Canadian provider perspectives on Collagenase Clostridium histolyticum for the treatment of Peyronie’s disease and the impact of its discontinuation.

Intralesional Collagenase Clostridium histolyticum (CCh) was the first non-surgical therapy approved for Peyronie’s disease (PD). However, CCh’s cost and poor market uptake has led to its discontinuation in Europe and Canada.